Enoxaparin thromboprophylaxis in hospitalized obese pediatric patients.

Juwon YimAfrin JahanNikolay BraykovNina D MurphyGary M Woods

Published in: Pediatric blood & cancer (2024)

Increased initial dosing and/or anti-Xa level monitoring should be considered in adolescents with severe obesity receiving enoxaparin thromboprophylaxis.

Keyphrases

venous thromboembolism
weight loss
metabolic syndrome
direct oral anticoagulants
type diabetes
young adults
insulin resistance
adipose tissue
bariatric surgery
physical activity
early onset
high fat diet induced
weight gain
obese patients
skeletal muscle
drug induced
atrial fibrillation